# Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia

> **NCT02791763** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 355 (actual)

## Conditions studied

- Anaemia

## Interventions

- **DRUG:** 1 to 4 mg tablets of GSK1278863
- **DRUG:** 6 mg GSK1278863 tablet
- **DRUG:** Epoetin beta pegol

## Key facts

- **NCT ID:** NCT02791763
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-06
- **Primary completion:** 2018-10-26
- **Final completion:** 2018-10-26
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2021-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02791763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02791763, "Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02791763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*